X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel
therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of
its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common
stock. All of the securities in the offering will be sold by X4. The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Cowen and Stifel are acting as joint book-running managers and representatives of the underwriters for the offering. Canaccord
Genuity is acting as lead manager of the offering.
The offering will be made only by means of a written prospectus and related prospectus supplement forming part of a shelf
registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) on January 25, 2019 and
declared effective by the SEC on February 19, 2019. A preliminary prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering will be filed with the SEC and will be available at the SEC’s website located at
www.sec.gov, copies of which may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at 631-274-2806, and from Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or
by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or other jurisdiction.
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases,
including primary immunodeficiencies and cancer. X4’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays
a central role in immune surveillance. X4’s most advanced product candidate, mavorixafor (X4P-001), will be commencing a global
Phase 3 pivotal trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease, in the second quarter of
2019 and is currently also under investigation in a Phase 2a clinical trial in clear cell renal cell carcinoma. X4 was founded and
is led by a team with extensive product development and commercialization expertise, including several former members of the
Genzyme leadership team, and is located in Cambridge, Massachusetts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements
include statements regarding the completion of the proposed public offering. These statements are subject to various risks and
uncertainties, actual results could differ materially from those projected and X4 cautions investors not to place undue reliance on
the forward-looking statements in this press release. These risks and uncertainties include, without limitation, risks and
uncertainties related to whether or not X4 will be able to raise capital through the sale of shares of common stock (or pre-funded
warrants to purchase common stock in lieu thereof) or the exercise of the Class A warrants to purchase common stock, the final
terms of the proposed offering, market conditions and satisfaction of customary closing conditions related to the public offering.
There can be no assurance that X4 will be able to complete the public offering on the anticipated terms, or at all. Any
forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks
and uncertainties described in X4’s most recent Annual Report on Form 10-K filed with the SEC, and in other filings X4 makes with
the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect
subsequently occurring events or circumstances.
Investors:
Stephanie Carrington
Westwicke, an ICR company
646-277-1282
Stephanie.Carrington@icrinc.com
Media:
Darcie Robinson
Westwicke, an ICR company
203-919-7905
Darcie.robinson@icrinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190411005837/en/